Hepion Pharmaceuticals, Inc.

NasdaqCM:HEPA 株式レポート

時価総額：US$3.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Hepion Pharmaceuticals マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

John Brancaccio

最高経営責任者

US$81.0k

報酬総額

CEO給与比率n/a
CEO在任期間less than a year
CEOの所有権0.006%
経営陣の平均在職期間データなし
取締役会の平均在任期間2yrs

経営陣の近況

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

CEO（最高経営責任者

John Brancaccio (76 yo)

less than a year

在職期間

US$81,000

報酬

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...

取締役

名称ポジション在職期間報酬所有権
John Brancaccio
Interim CEO11.4yrsUS$81.00k0.0060%
$ 224.1
Timothy M. Block
Independent Director10.9yrsUS$72.90k0.0060%
$ 224.1
Vlad Ratziu
Member of Scientific Advisory Board1.6yrsデータなしデータなし
Rohit Loomba
Member of Scientific Advisory Board1.6yrsデータなしデータなし
Stephen A. Harrison
Scientific Advisory Board Chair5.2yrsデータなしデータなし
Nikolai Naoumov
Member of Scientific Advisory Board1.6yrsデータなしデータなし
Philippe Gallay
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Michael Purcell
Independent Directorless than a yearデータなしデータなし
Yury Popov
Member of Scientific Advisory Board1.6yrsデータなしデータなし
Kaouthar Lbiati
Independent Director2.3yrsUS$80.50kデータなし

2.0yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: HEPAの 取締役会 は 経験豊富 ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。